First patient in for landmark Tourette Syndrome study
(Stockholm, 16 February, 2022.) Asarina Pharma announces today that ‘First Patient First Visit’ has taken place in its phase IIa clinical study in Tourette syndrome… Read More »First patient in for landmark Tourette Syndrome study